Correspondence 0001493152-25-003730 from Processa Pharmaceuticals, Inc. (PCSA)

Processa Pharmaceuticals, Inc.
Date: Jan. 27, 2025 · CIK: 0001533743 · Accession: 0001493152-25-003730

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 333-283986

Date

Jan. 27, 2025

Author

George Ng

Form

CORRESP

Company

Processa Pharmaceuticals, Inc.

Letter

Processa Pharmaceuticals, Inc.

Coca Cola Drive, Suite 106

Hanover, Maryland 21076

January 27, 2025

VIA EDGAR

United States Securities and Exchange Commission

Division of Corporation Finance

F Street, NE

Washington, D.C. 20549

Attention: Mr. Christopher Edwards

Re: Processa Pharmaceuticals, Inc.

Registration Statement on Form S-1 (Registration No. 333-283986)

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant, Processa Pharmaceuticals, Inc. (the “Registrant”), hereby requests acceleration of effectiveness of its above-referenced Registration Statement to 4:30 P.M., Eastern time, on January 27, 2025, or as soon as practicable thereafter. The Registrant respectfully requests that you notify Mr. Michael Kirwan of Foley & Lardner LLP of such effectiveness by a telephone call to (904) 633-8913.

Very truly yours,
Processa Pharmaceuticals, Inc.

Show Raw Text

CORRESP
1
filename1.htm

Processa
Pharmaceuticals, Inc.

7380
Coca Cola Drive, Suite 106

Hanover,
Maryland 21076

January
27, 2025

VIA
EDGAR

United
States Securities and Exchange Commission

Division
of Corporation Finance

100
F Street, NE

Washington,
D.C. 20549

Attention:
Mr. Christopher Edwards

  Re:
  Processa Pharmaceuticals,
  Inc.

  Registration Statement
  on Form S-1 (Registration No. 333-283986)

Ladies
and Gentlemen:

Pursuant
to Rule 461 under the Securities Act of 1933, as amended, the undersigned registrant, Processa Pharmaceuticals, Inc. (the “Registrant”),
hereby requests acceleration of effectiveness of its above-referenced Registration Statement to 4:30 P.M., Eastern time, on January
27, 2025, or as soon as practicable thereafter. The Registrant respectfully requests that you notify Mr. Michael Kirwan of Foley &
Lardner LLP of such effectiveness by a telephone call to (904) 633-8913.

    Very truly yours,

    Processa Pharmaceuticals, Inc.

    By:
  /s/ George
  Ng

  George Ng

  Chief Executive Officer

SecProbe.io